Clinical trial
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's…
NCT00039130 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00039130 |
|---|---|
| Title | Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia |
| Official title | Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate and 3 more |
| Enrollment | 105 |
| Start date | May 1, 2002 |
| Primary completion | Sep 1, 2010 |
| Completion | Oct 1, 2014 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 21, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: